Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

LGC licenses Orchid to test for drug metabolising gene

10.06.2002


LGC, the UK`s leading independent provider of genetic testing services, has issued its first testing licence for the key DNA variant in the drug metabolising gene CYP2D6 to Orchid BioSciences Inc. LGC holds the exclusive commercialisation rights to the patented diagnosis of this `poor metaboliser` gene variation and, in granting this first licence, will make access to this beneficial technology available to leading companies internationally for the first time.



The gene CYP2D6 controls an enzyme in the human liver. About 6% of the Caucasian population have a genetically pre-determined deficiency in this enzyme. This means that they do not metabolise about 20% of currently prescribed medications correctly. The genetic variation in the gene CYP2D6, known as *4, was first invented by Imperial Cancer Research Fund (ICRF) scientists and patented by the Fund in the early 1990s. One of the inventors, Professor Roland Wolf, joined the University of Dundee and ICRF granted the University an exclusive licence. Subsequently, the University granted exclusive rights to LGC to commercialise and sub-license the technology in September 2001.

Dr Paul Debenham, Director of Life Sciences at LGC, and who has found himself to have the poor metaboliser gene status, said: "There is tremendous excitement in the field of genetically pre-determined drug metabolism, known as pharmacogenetics, about the growing understanding of how each individual may differ in their ability to respond to various medications, and in particular to avoid serious adverse reactions. This is an exciting start to the expansion of the opportunity for the public at large to benefit from understanding their own capability to respond to prescribed medications."


The first sub-licensee, Orchid BioSciences Inc, has taken a non-exclusive licence for North America for an undisclosed sum, and the gene diagnostic will be an essential element in their Orchid GeneShield business focused on pharmacogenomics and personalised medicine. Product offerings being developed by the Orchid GeneShield business are designed to enable physicians, patients and health care providers to better match the right drug to the right patient. LGC is also in discussions with other companies to respond to their interests in licensing and developing tests built around the *4 genetic test.

Dr Richard Worswick, LGC`s Chief Executive, said: "We foresee this as the first of many licensing deals and the forerunner of tremendous growth in the pharmacogenetics business sector. We are most pleased to have completed this non-exclusive agreement with Orchid BioSciences for North America."

Imelda Topping | alfa
Further information:
http://www.lgc.co.uk/news_story.asp?strareano=47_2&intelement=4234

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Structured light and nanomaterials open new ways to tailor light at the nanoscale

23.04.2018 | Physics and Astronomy

On the shape of the 'petal' for the dissipation curve

23.04.2018 | Physics and Astronomy

Clean and Efficient – Fraunhofer ISE Presents Hydrogen Technologies at the HANNOVER MESSE 2018

23.04.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>